Tjitske S. R. van Engelen

Tjitske S. R. van Engelen

Auto-generated profile, based on publicly available information

Tjitske S. R. van Engelen

Centre for Infection and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Critical Care Clinics
Verified
Journal Article
Closed access
TETjitske S.R. van Engelen
Tjitske S.R. van Engelen
WWWillem Joost Wiersinga
Willem Joost Wiersinga
BSBrendon P. Scicluna
Brendon P. Scicluna
TPTom van der Poll
Tom van der Poll

8 August 2018 in Diagnostic and Prognostic Research
Verified
Journal Article
Open access
PDF file
IBInge A. H. van Den Berk
Inge A. H. van Den Berk
MKMaadrika M. N. P. Kanglie
Maadrika M. N. P. Kanglie
TETjitske S. R. van Engelen
Tjitske S. R. van Engelen
SBShandra Bipat
Shandra Bipat
MDMarcel G.W. Dijkgraaf
Marcel G.W. Dijkgraaf
JSJaap Stoker
Jaap Stoker
Chest X-ray has been the standard imaging method for patients suspected of non-traumatic pulmonary disease at the emergency department (ED) for years. Recently, ultra-low-dose chest computed tomography (ULD chest CT) has been introduced, which provides substantially more detailed information on pulmonary conditions that may cause pulmonary disease, with a dose in the order of chest X-ray (0.1 vs. 0.05 mSv). The OPTimal IMAging strategy in patients suspected of non-traumatic pulmonary disease at the emergency department: chest X-ray or CT (OPTIMACT) study is a randomized trial designed to evaluate the effectiveness of replacing chest X-ray for ULD chest CT in the diagnostic work-up of patients suspected of non-traumatic pulmonary disease at the ED. Two thousand four hundred patients presenting at the ED with pulmonary complaints and suspected of non-traumatic pulmonary disease will be enrolled in this multicenter, pragmatic, randomized trial. During randomly assigned periods of one calendar month, either conventional chest X-ray or ULD chest CT scan will be used as the imaging strategy. Randomization will rely on computer-generated blocks of 2 months to control for seasonal effects. Chest X-ray and ULD chest CT will be performed in a standardized way, after obtaining the clinical history and performing physical examination and initial laboratory tests. The primary outcome measure is functional health at 28 days. Secondary outcome measures are mental health, length of hospital stay, mortality within 28 days, quality-adjusted life years (QALYs) during the first 28 days, correct diagnoses at ED discharge as compared to the final post hoc diagnosis, and number of patients in follow-up because of incidental findings on chest X-ray or ULD chest CT. In an economic evaluation, we will estimate total health care costs during the first 28 days. This pragmatic trial will clarify the effects of replacing chest X-ray by ULD chest CT in daily practice, in terms of patient-related health outcomes and costs, in the diagnostic work-up of patients suspected of non-traumatic pulmonary disease at the ED. The OPTIMACT trial is registered in the Netherlands National Trial Register under number NTR6163 . The date of registration is December 6, 2016.

9 March 2018 in Critical Care
Verified
Journal Article
Open access
PDF file
JSJelmer Savelkoel
Jelmer Savelkoel
TCTheodora A. M. Claushuis
Theodora A. M. Claushuis
TETjitske S. R. van Engelen
Tjitske S. R. van Engelen
LSLuuk J. J. Scheres
Luuk J. J. Scheres
WWW. Joost Wiersinga
W. Joost Wiersinga

31 January 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
XBXanthe Brands
Xanthe Brands
TETjitske S R van Engelen
Tjitske S R van Engelen
FVFloris M C de Vries
Floris M C de Vries
BHBastiaan W Haak
Bastiaan W Haak
AKAugustijn M Klarenbeek
Augustijn M Klarenbeek
TPTom van der Poll
Tom van der Poll
Strongly elevated ferritin levels have been proposed to reflect systemic hyperinflammation in patients admitted to the intensive care unit. Knowledge of the incidence and pathophysiological implications of hyperferritinemia in patients with acute infection admitted to a non–intensive care setting is limited. We determined the association between hyperferritinemia, defined by 2 cutoff values (500 and 250 ng/mL), and aberrations in key host response mechanisms among patients with community-acquired pneumonia (CAP) on admission to a general hospital ward (clinicaltrials.gov NCT02928367; trialregister.nl NTR6163). Plasma ferritin levels were higher in patients with CAP (n = 174; median [interquartile ranges], 259.5 [123.1–518.3] ng/mL) than in age- and sex-matched controls without infection (n = 50; 102.8 [53.5–185.7] ng/mL); P < .001); they were ≥500 ng/mL in 46 patients (26%) and ≥250 ng/mL in 90 (52%). Measurements of 26 biomarkers reflective of distinct pathophysiological domains showed that hyperferritinemia was associated with enhanced systemic inflammation, neutrophil activation, cytokine release, endothelial cell activation and dysfunction, and activation of the coagulation system. Results were robust across different cutoff values. Hyperferritinemia identifies patients with CAP with a broad deregulation of various host response mechanisms implicated in the pathogenesis of sepsis. This could inform future therapeutic strategies targeting subgroups within the CAP population.

25 September 2024 in Thorax
Verified
Journal Article
Open access
PDF file
TRTom D Y Reijnders
Tom D Y Reijnders
PLPierre-François Laterre
Pierre-François Laterre
BFBruno François
Bruno François
MSMiguel - Sánchez-García
Miguel - Sánchez-García
TETjitske S R van Engelen
Tjitske S R van Engelen
TPTom Van der Poll
Tom Van der Poll
Mesenchymal stem cells (MSC) have immune regulatory properties that may ameliorate pathophysiological processes in sepsis. We determined the effect of allogeneic adipose-derived MSCs (Cx611) on the host response during sepsis due to community-acquired bacterial pneumonia (CABP) by measuring 29 plasma biomarkers and blood transcriptomes at six time points in 82 patients randomised to two intravenous infusions of Cx611 or placebo. Cx611 treatment enhanced several endothelial cell and procoagulant response plasma biomarkers, and led to increased expression of pathways related to innate immunity, haemostasis and apoptosis. Cx611 infusion in sepsis due to CABP is associated with broad host response alterations.

8 January 2016 in Molecular Medicine
Verified
Journal Article
Open access
TLTian Lin
Tian Lin
JLJialin Liu
Jialin Liu
FHFeng Huang
Feng Huang
TETjitske S R van Engelen
Tjitske S R van Engelen
STSujatha R Thundivalappil
Sujatha R Thundivalappil
HWH Shaw Warren
H Shaw Warren
Infusion of the heme-binding protein hemopexin has been proposed as a novel approach to decrease heme-induced inflammation in settings of red blood cell breakdown, but questions have been raised as to possible side effects related to protease activity and inhibition of chemotaxis. We evaluated protease activity and effects on chemotaxis of purified plasma hemopexin obtained from multiple sources as well as a novel recombinant fusion protein Fc-hemopexin. Amidolytic assay was performed to measure the protease activity of several plasma-derived hemopexin and recombinant Fc-hemopexin. Hemopexin was added to the human monocyte culture in the presence of lipopolysaccharides (LPS), and also injected into mice intravenously (i.v.) 30 min before inducing neutrophil migration via intraperitoneal (i.p.) injection of thioglycolate. Control groups received the same amount of albumin. Protease activity varied widely between hemopexins. Recombinant Fc-hemopexin bound heme, inhibited the synergy of heme with LPS on tumor necrosis factor (TNF) production from monocytes, and had minor but detectable protease activity. There was no effect of any hemopexin preparation on chemotaxis, and purified hemopexin did not alter the migration of neutrophils into the peritoneal cavity of mice. Heme and LPS synergistically induced the release of LTB4 from human monocytes, and hemopexin blocked this release, as well as chemotaxis of neutrophils in response to activated monocyte supernatants. These results suggest that hemopexin does not directly affect chemotaxis through protease activity, but may decrease heme-driven chemotaxis and secondary inflammation by attenuating the induction of chemoattractants from monocytes. This property could be beneficial in some settings to control potentially damaging inflammation induced by heme.